Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
NEJM • 2/25/2026 – 2/26/2026
Summary
The article titled "Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC" was published in the New England Journal of Medicine, Volume 394, Issue 9, on February 26, 2026, spanning pages 933-936.
Advertisement
Lindy Score Breakdown (V4.2)
51d
Age
1
Sources
from cluster
1219
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1219/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1219/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 51 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Opinion: Don’t believe headlines saying that vaccine skepticism is widespread
Stat News • Today
STAT+: Up and down the ladder: The latest comings and goings
Stat News • Today
The deadly consequences of ICE detention
Stat News • Today
STAT+: Kennedy focuses on affordability, combating fraud in Capitol Hill hearings
Stat News • 1 day ago
STAT+: RFK Jr. begins his testimony marathon
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Stat News • Today
STAT+: FDA panel will meet to discuss allowing broader access to certain peptides
Stat News • 2 days ago
STAT+: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway
Stat News • 1 day ago
STAT+: CMS proposes rolling back breakthrough device payment flexibilities
Stat News • 2 days ago
STAT+: Medicare may nix breakthrough device payment pathway
Stat News • 1 day ago